Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 19/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimasertib SCHEMBL29604438 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL29358435 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL2021184 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL2720659 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL18260054 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL29867955 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| SCHEMBL31108067 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| SCHEMBL2018933 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2019046 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2018500 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885PRKCZ 3239/4885 |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885PRKCZ 3233/4885 |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885PRKCZ 3233/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885PRKCZ 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.